Fig. 5. Effects of anti-CD90.2 mAb treatment in Rag1^−/− AD mouse model. (A) Clinical symptom scores and transepidermal water loss levels were significantly decreased in the anti-CD90.2 mAb-treated mouse group, compared to isotype control mAb-treated group. (B) Skin lesions from the anti-CD90.2 mAb-treated group showed decreased thickening of the epidermal and dermal layers (scale bars = 200 µm).

Data are expressed as a mean ± SEM (n = 6 per group).

AD = atopic dermatitis, Af = Aspergillus fumigatus, TEWL = transepidermal water loss.

^*P < 0.05 and ^**P < 0.01, compared with the isotype-treated group; ^#P < 0.05 and ^##P < 0.01, compared with the control group.